[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-neuropathic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-neuropathic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,74,105,140,165,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100550146","pain-phenotyping-in-patients-with-neuropathic-pain-after-spinal-cord-injury-100550146",false,"NCT06443281","Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal injury cohort - general inclusion criteria:\n* Aged between 18-80 years\n* Traumatic and non-traumatic etiology\n* Para- and tetraplegic SCI\n* Complete and incomplete SCI\n* SCI with and without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* SCI since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* SCI since more than one year\n* Control cohorts with peripheral neuropathy:\n* General inclusion criteria:\n* Aged between 18-80 years\n* Neurological disorder affecting the peripheral nervous system (i.e., peripheral neuropathy)\n* Peripheral neuropathy with or without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* Peripheral neuropathy since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* Peripheral neuropathy since more than one year\n* Control cohorts without neuropathy \u002F healthy volunteers\n* General inclusion criteria:\n* Aged between 18-80 years\n* No medical condition affecting the peripheral and\u002For central nervous system (e.g., pain, systemic disease, psychological disorder)\n\nExclusion Criteria:\n\n* Inability to follow study instructions\n* Pregnancy\n* Medically manifested psychological disorder\n* Medical condition affecting the peripheral and\u002For central nervous system other than the desired experimental condition (e.g., additional peripheral neuropathy in the SCI cohort)",true,"ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.",[25,26,27,28],"Spinal Cord Injuries","Pain, Neuropathic","Nociceptive Pain","Neuropathy","RECRUITING","2026-05-12",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":33},"2024-04-17",{"date":37,"type":21},"2030-04-30",{"name":39,"class":40},"University of Zurich","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100489489","scrambler-therapy-for-corticobasal-syndrome-associated-pain-100489489","NCT05653778","Scrambler Therapy for Corticobasal Syndrome-Associated Pain","ST-CBS","Inclusion Criteria:\n\n* men and women, ≥50 years of age or older with CBS with an average daily pain rating of \\> 4 out of 10, using the following question from the Brief Pain Inventory: \"Please rate your pain by circling the one number that best describes your (abdominal) pain\u002Fdiscomfort on average over the past week. (Scale 0-10; 0= No pain, 10= Pain as bad as you can imagine)\n* English speakers or English proficiency\n* They must have a life expectancy \\> 90 days per their treating neurologist.\n* The patient must be able to understand the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women, nursing women, women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device, surgical sterilization, subcutaneous implants, abstinence, etc.). Other exclusions include the following:\n* Use of an investigational agent for pain control concurrently or within the past 30 days,\n* History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation;\n* Patients with implantable drug delivery systems, e.g. Medtronic Synchromed, baclofen pumps.\n* Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, cochlear implants, aneurysm clips, vena cava clips and skull plates. (Metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed).\n* Medical exclusions include: patients with a history of myocardial infarction or ischemic heart disease within the past six months; patients with history of epilepsy, brain damage, or symptomatic brain metastases; skin conditions such as open sores that would prevent proper application of the electrodes; or other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study.","50 Years","89 Years",{"count":52,"type":21},25,"INTERVENTIONAL",[55],"NA","The goal of this pilot trial is to test whether scrambler therapy (ST) is an effective treatment for neuropathic pain in patients with corticobasal syndrome (CBS).\n\nThe main question it aims to answer is:\n\nWill ST reduce pain scores by at least 33% at one month in this pilot trial, justifying further multi-center trials?\n\nParticipants will:\n\n* be randomly assigned treatment from either transcutaneous electrical nerve stimulation (TENS) or ST for pain initially (eventually all patients will receive ST).\n* have superficial electrocardiogram (ECG) electrodes placed on the dermatomes involved with pain\n* obtain treatment lasting 30-40 minutes or until pain relief is obtained\n\nResearchers will compare patient's response to pain relief with TENS and ST to determine if ST is an effective treatment for central neuropathic pain.",[58,59,26],"Corticobasal Degeneration","Corticobasal Syndrome",[58,61,62,63,64],"scrambler therapy","Corticobasal syndrome","neuropathic pain","neuropathy","2026-01-12",{"date":67,"type":33},"2026-01-13",{"date":69,"type":33},"2024-04-05",{"date":71,"type":21},"2027-02",{"name":73,"class":40},"Johns Hopkins University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":84,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":41},"100505643","phase-1-2r6r-hydroxynorketamine-for-the-treatment-of-neuropathic-pain-100505643","NCT05864053","(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain","(2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.","HNK","Inclusion Criteria:\n\n* Adult patients (18 to 75 years) with an established diagnosis of chronic (\\> 3 month) NP of the extremities.\n* Presence of NP as determined at screening using the 10 item Neuropathic Pain Questionnaire (DN4), with a score of ≥4 required for study inclusion.\n* Ability to read and write English sufficiently to complete study related procedures.\n* A body mass index (BMI) (weight \\[kg\\]\u002Fheight\\[m \\]) between 18 and 35 kg\u002Fm (inclusive) and weighs between 50 kg and 120 kg (110 - 264 pounds).\n* Blood pressure with subject is in a supine position for approximately 5 minutes between 90 and 145 mmHg systolic and no higher than 90 mmHg diastolic at baseline.\n* A 12-lead ECG with no clinically significant abnormality as judged by the Investigator and QTc interval ≤ 450 milliseconds at baseline.\n* Resting pulse rate between 45 and 100 beats per minute.\n* Clinical laboratory findings and liver function tests within the normal range, or if outside of the normal ranges, deemed not clinically significant in the opinion of the PI.\n* Agree to provide written informed consent and comply with the rules regarding consumption of alcohol, caffeinated beverages, and tobacco\u002Fnicotine products during the study.\n* Patients may be taking scheduled or as needed medications for their chronic neuropathic pain and agree to continue taking the scheduled medications throughout the study period.\n* If the subject experiences pain relief they may elect not to take as needed medications.\n\nExclusion Criteria:\n\n* Subjects with suspected increased intracranial or intraocular pressure.\n* Subjects that have previously received ketamine for the treatment of a chronic pain diagnoses.\n* Previous or current participation in any clinical study with an investigational drug, device, or biologic within 30 days.\n* Subjects with severe medical illness including (but not limited to) hepatic, cardiovascular, pulmonary, renal, hematologic, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease that in the opinion of the PI would endanger the safety of the subject or the validity of the study results.\n* Clinically significant acute illness in the 2 weeks prior to dosing.\n* Inability to effectively communicate with research staff.\n* Subjects with known liver disease.\n* Widespread pain or a diagnosis of fibromyalgia.\n* Current diagnosis of mental illness.\n* Pregnancy.\n* Allergy to ketamine or any study drug.\n* Consumption of beverages or food that contain alcohol, grapefruit, poppy seeds, Brussel sprouts, pomegranate, broccoli, char-grilled meat within 2 days prior to drug administration.\n* Use of tobacco or nicotine-containing products within 4 weeks prior to drug administration.\n* Poor peripheral venous access.\n* Subjects in the opinion of the PI should not participate in the study.","75 Years",{"count":52,"type":21},[85,86],"PHASE1","PHASE2","The goal of this randomized double blind three way (1:1:1) cross over clinical trial is to evaluate the effectiveness and duration of analgesia of a single infusion of (2R,6R)-HNK 0.5mg\u002Fkg compared with ketamine 0.5mg\u002Fkg and saline with a 5-week interval between treatments on pain, pain qualities, physical function, pain interference, sleep disturbance and quality of life in subjects with neuropathic pain of the extremities.\n\nThe questions that this study will address are:\n\n1. What is the analgesic efficacy of (2R,6R)-HNK on pain intensity and pain qualities in patients with chronic (\\>3 month) neuropathic pain (NP).\n2. What will be the effective duration of a single infusion of (2R,6R)-HNK in patients with NP.\n3. Will (2R,6R)-HNK reduce pain related effects including interference in daily activities of life, sleep disturbances and change the qualities of pain reported by patients.\n\nParticipants will receive each of the three study drugs in a random order at 5-week intervals over a 15 week period. The drug will be administered as a 45-minute infusion.\n\nParticipants will complete quantitative sensory and pain evaluations and complete patient reported pain outcomes prior to receiving the first study drug and at 7, 14 and 21 and 35 days following study drug administration.",[26],[90,91,92,93,94,95],"pain","pain, chronic","pain, neuropathic","non-opioid analgesic","ketamine","(2R,6R)-hydroxynorketamine","2026-01-05",{"date":98,"type":33},"2026-01-07",{"date":100,"type":33},"2024-09-19",{"date":102,"type":21},"2026-12",{"name":104,"class":40},"Rush University Medical Center",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":53,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100385529","phase-2-ozone-therapy-in-chemotherapy-induced-peripheral-neuropathy-rct-o3npiq-100385529","NCT04299893","Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)","Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)","O3NPIQ","Inclusion Criteria:\n\n* 1\\. Adults \\> = 18 years old.\n* 2\\. Any kind of cancer in any stage, treated with any kind of chemotherapy, and life expectancy \\> = 6 months.\n* 3\\. Clinical diagnosis of painful chemotherapy-induced peripheral neuropathy, toxicity Grade 2 or higher according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0, for \\> = 3 months and without the inclusion of new treatments for pain and\u002For neuropathy for \\> = 1 month.\n* 4\\. \"Average pain\" \\> = 3\u002F10 according to the Brief Pain Inventory-Short Form (BPI-SF) \\> = 3 months beyond chemotherapy completion.\n* 5\\. Pregnant women cannot participate in the clinical trial.\n* 6\\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from the 14 days prior to the first ozone therapy session up to 14 days after the last one.\n* 7\\. Patients who have signed and dated the study 's specific informed consent\n\nExclusion Criteria:\n\n* 1\\. Age \\\u003C 18 years old.\n* 2\\. Pregnancy at the time of enrollment.\n* 3\\. Women with childbearing potential who are unwilling to perform a pregnancy test and\u002For employ adequate contraception from the 14 days prior to the first ozone therapy session up to 14 days after the last one.\n* 4\\. Clinical suspicion that peripheral neuropathy (compressive or diabetic neuropathy) in the same area prior to receiving neurotoxic chemotherapy.\n* 5\\. Psychiatric illness or social situations that would limit compliance with study requirements.\n* 6\\. Those who are unable to fill in the scales used to measure quality of life variables\n* 7\\. Specific liver enzymes \\[Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \\> 5 times the upper limit of normal\n* 8\\. Increased creatinine \\> 3 times the upper limit of normal.\n* 9\\. Hemodynamically or clinically unstable patients or uncontrolled severe illness.\n* 10\\. Uncontrolled cancer disease.\n* 11\\. Leptomeningeal carcinomatosis.\n* 12\\. Life expectancy \\\u003C 6 months\n* 13\\. Contraindication or disability for rectal ozone administration or to attend scheduled treatments.\n* 14\\. Known allergy to ozone.\n* 15.Patients who do not meet all the inclusion criteria.","100 Years",{"count":115,"type":21},42,[86,117],"PHASE3","The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy",[120,26,121],"Chemotherapy-induced Peripheral Neuropathy","Pain Syndrome",[123,124,125,90,126,127,128,129],"complementary and integrative medicine","cost-effectiveness ratio","chemotherapy-induced peripheral neuropathy","ozone therapy","quality of life related to health","shared decision-making tool","randomized controlled trial","2025-08-25",{"date":132,"type":33},"2025-09-02",{"date":134,"type":33},"2020-11-30",{"date":136,"type":21},"2027-12-31",{"name":138,"class":40},"Bernardino Clavo, MD, PhD",2,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":53,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100439984","surgical-treatments-for-postamputation-pain-100439984","NCT05009394","Surgical Treatments for Postamputation Pain","Inclusion Criteria:\n\n* The participant must have a major limb amputation.\n* The participant is ≥ 18 years old at the time of consent.\n* The participant must be in generally good health to undergo a surgical intervention, as per the clinical investigator's opinion.\n* Time since the last amputation must be over a year at the time of consent.\n* The participant must have an average residual limb pain score equal or greater than 4 on the Numerical Rating Scale (NRS, 0-10) after the baseline period.\n* If the participant has been prescribed pharmacological treatments for pain, there must be no variations in dosage (steady consumption) for at least 1 month before the screening visit.\n* If the participant has been prescribed non-pharmacological treatments for pain, such as spinal cord stimulation, transcutaneous electrical nerve stimulation, and mirror therapy, the treatment must have ended at least 1 month before the screening visit.\n* The participant must have a stable prosthetic fitting for at least a month before the screening visit.\n* The participant has a sufficient understanding of the language in which the assessments will be conducted, as per the clinical investigator's opinion.\n\nExclusion Criteria:\n\n* Neurological or other conditions that affect nerve regeneration for the nerve to be treated.\n* Active infection in the residual limb.\n* Prior RPNI or TMR surgery of the nerve to be treated (with painful neuroma) to address postamputation pain.\n* Mental disorders (e.g., schizophrenia, paranoia, psychosis, etc.), reluctance, or language difficulties that result in difficulty understanding the meaning of study participation.\n* Ongoing participation in a clinical study that the clinical investigator deems detrimental to participation in this study.",{"count":147,"type":21},110,[55],"This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.",[151,152,153,26,154],"Residual Limb Pain","Amputation Neuroma","Phantom Limb Pain","Pain, Nerve","2025-01-07",{"date":157,"type":33},"2025-01-09",{"date":159,"type":33},"2023-06-20",{"date":161,"type":21},"2029-06",{"name":163,"class":40},"Prometei Pain Rehabilitation Center",9,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":53,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":41},"100513683","novel-stimulation-patterns-to-improve-the-effectiveness-of-spinal-cord-stimulation-100513683","NCT05968664","Novel Stimulation Patterns to Improve the Effectiveness of Spinal Cord Stimulation","DYNAMO","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Age ≥ 22\n* Chronic pain of the trunk and\u002For limbs for at least 6 months\n* Baseline average daily overall pain score of \\>60 (on a scale of 0-100mm) on the Visual Analog Scale related to pain of the back and\u002For limbs\n* Failed ≥3 medically supervised treatments (i.e. pain medications, physical therapy, facet joint\u002Fmedial branch nerve blocks, acupuncture), and treatment with \\>2 classes of medications\n* Stable pain-related medication regimen 4 weeks prior to the trial. Patients will be asked to not increase or add pain-related medication during the study period\n* No back surgery within 6 months prior to Screening\n* Consumed an average total daily morphine equivalent of ≤200 mg during the 30 days prior to Screening.\n* Baseline Oswestry Disability Index score ≥40 and ≤80\n* Eligible candidate for SCS from a psychological and psychiatric standpoint as determined within 180 days prior to Baseline Visit, per site's routine screening process\n* Able to independently read and complete all questionnaires and assessments provided in English\n* Female candidates of child-bearing potential agree to use contraception during the study period\n* Deemed to be a good candidate for spinal cord stimulation by the PI, and a board certified pain management physician\n* Willing to cooperate with study requirements\n\nExclusion Criteria:\n\n* Patient exhibits catastrophization based on physician evaluation (e.g., average overall daily pain intensity of 100 on a 0-100mm visual analog scale, every day during the 7 days prior to Screening, based on patient recall\n* Pain originating from peripheral vascular disease\n* Active treatment for cancer in past 6 months\n* Involved in disability litigation\n* High surgical risk including documented history of allergic response to titanium or silicone, current systemic infection, or local infection in close proximity to anticipated surgical field\n* Body mass index ≥ 45 at Screening\n* Terminal illness with anticipated survival \\\u003C 12 months\n* Participant is immunocompromised\n* Significant cognitive impairment at Screening that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study\n* Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study\n* Previous spinal cord stimulation trial\u002Fimplant or is already implanted with an active implantable device(s) (e.g. drug pump, implantable pulse generator)\n* A pregnant female or a female of childbearing potential planning to get pregnant during the course of the study\n* Plan to receive any massage or manipulation directly over the leads or by the anticipated location of the IPG or treatments that involve sudden jerking motions of the torso at any\n* Existing medical condition that is likely to require the use of diathermy\n* Any injury or medical\u002Fpsychological condition that might be significantly exacerbated by the implant surgery or the presence of an implantable stimulator or otherwise compromise subject safety\n* Unable to operate the study devices including wrist-worn biosensor and mobile app\n* Documented history of substance abuse or dependency in the 6 months prior to baseline","22 Years",{"count":174,"type":21},43,[55],"The goal of this study is to compare pain outcomes achieved by spinal cord stimulation (SCS) using time varying stimulation patterns with pain outcomes achieved by current standard of care SCS.",[178,26,179],"Chronic Pain","Neuropathic Pain",[181,182,183,28],"Chronic pain","Spinal Cord Stimulation","Spinal cord","2024-11-20",{"date":186,"type":33},"2024-11-22",{"date":188,"type":33},"2024-08-01",{"date":190,"type":21},"2028-01",{"name":192,"class":40},"Ashwin Viswanathan",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":203,"conditions":204,"keywords":211,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100562541","feasibility-of-using-an-app-for-managing-phantom-limb-pain-associated-with-combat-injury-in-ukraine-pamela-100562541","NCT06604507","Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Injury in Ukraine (PAMELA)","Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Amputation in Ukraine: a Quantitative & Qualitative Observational Trial in the 'Prevention and Management of Phantom Limb Pain' Project","PAMELA","Inclusion Criteria:\n\n* Amputee has given written informed consent for participation in the study.\n* Male or Female\n* Age - no restriction but adult\n* Have undergone amputation of one limb, upper or lower.\n\nExclusion Criteria:\n\nFor Graded Motor Imagery \u002F Mirror therapy Amputees with disorders such as post-traumatic stress disorders should perform mirror therapy only after initial assessment by the therapist carrying out the treatment, as the mirror image of two intact limbs might elicit memories associated with the trauma",{"count":202,"type":21},200,"In Ukraine, since the beginning of the full-scale war on February 24, 2022, a large number of individuals have lost a limb(s). Many of these amputees cannot access appropriate care in terms of pain management and rehabilitation. Consequently, healthcare providers in Ukraine have been seeking assistance from international, professional bodies to improve the care offered to amputees - soldiers and civilians.\n\nPain related to an amputation is chronic and so non-pharmacological approaches, rather than pharmacological, are appealing. In Germany, Routine Health, in Düsseldorf, have developed an app-based platform which offers amputees a variety of non-pharmacological management techniques.\n\nIn the PAMELA project, we will offer amputees and therapists in Ukraine, use of this app.\n\nThe app has been adapted for use in Ukraine.\n\nThe study will be carried out in 2 phases:\n\n1. A pilot in 5 rehabilitation centers to assess feasibility of using the app during one pre-defined 8-week treatment cycle, tailored to each amputee; amputees will be offered to use the app for another 4 weeks, independently\n2. Updating the app, based on experience gained in the pilot phase and sharing the app with amputees who wish to us it.",[205,206,207,208,26,209,210],"Amputation, Traumatic","Pain, Phantom","Pain, Acute","Pain, Chronic","Rehabilitation","War-Related Trauma",[212,213,214,215,216,91,92,217,218],"Non-pharmacological treatment","App, computer","amputation, traumatic","pain, phantom","pain, acute","rehabilitation","war-related trauma","NOT_YET_RECRUITING","2024-09-17",{"date":100,"type":33},{"date":223,"type":21},"2024-10-15",{"date":225,"type":21},"2026-12-31",{"name":227,"class":40},"Winfried Meißner",5]